Heinz Wiendl

Active 2000–2026

334
Papers
29,448
Citations
103
h-index
307
i10-index

Citations

Citations per year for Heinz Wiendl1986: 1 citations1994: 1 citations2000: 1 citations2001: 14 citations2002: 18 citations2003: 59 citations2004: 41 citations2005: 68 citations2006: 56 citations2007: 86 citations2008: 95 citations2009: 111 citations2010: 122 citations2011: 114 citations2012: 123 citations2013: 133 citations2014: 166 citations2015: 191 citations2016: 205 citations2017: 200 citations2018: 233 citations2019: 736 citations2020: 1,042 citations2021: 1,272 citations2022: 1,326 citations2023: 983 citations2024: 1,819 citations2025: 1,037 citations2026: 24 citations1987–1993: no citations, so these years are not shown1995–1999: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,798 citing papers, 20.2% of this breakdownGermany: 1,652 citing papers, 11.9% of this breakdownChina: 1,168 citing papers, 8.4% of this breakdownItaly: 881 citing papers, 6.4% of this breakdownUnited Kingdom: 875 citing papers, 6.3% of this breakdownFrance: 572 citing papers, 4.1% of this breakdownSwitzerland: 504 citing papers, 3.6% of this breakdownCanada: 485 citing papers, 3.5% of this breakdownSpain: 441 citing papers, 3.2% of this breakdownNetherlands: 406 citing papers, 2.9% of this breakdownAustralia: 381 citing papers, 2.7% of this breakdownAustria: 302 citing papers, 2.2% of this breakdown
0%20.2%Other 24.6%

Fields

  • Medicine59.1%
  • Neuroscience14.3%
  • Immunology and Microbiology12.6%
  • Biochemistry, Genetics and Molecular Biology10.6%
  • Health Professions1.3%
  • Nursing0.5%
  • Other1.6%

Topics

  • Multiple Sclerosis Research Studies9.9%
  • Neuroinflammation and Neurodegeneration Mechanisms5.9%
  • Peripheral Neuropathies and Disorders4.3%
  • Immunotherapy and Immune Responses3%
  • Immune Cell Function and Interaction2.9%
  • T-cell and B-cell Immunology2.9%
  • Other71.1%

Coauthors

All papers

Open in search
  1. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefanie Aeschbacher, Muhamed Barakovic, Andreas Buser, Andrew Chan, Giulio Disanto, Marcus D'Souza, Renaud Du Pasquier, Oliver Findling, Riccardo Galbusera, Kevin Hrusovsky, Michael Khalil, Johannes Lorscheider, Amandine Mathias, Annette Orleth, Ernst-Wilhelm Radue, Reza Rahmanzadeh, Tim Sinnecker, Suvitha Subramaniam, Jochen Vehoff, Sven Wellmann, Jens Wuerfel, Chiara Zecca - The Lancet Neurology 2022 cited by 601

  2. How patients with multiple sclerosis acquire disability

    Authors: , , , , , , , , , , , , , - Brain 2022 cited by 528

  3. Ofatumumab versus Teriflunomide in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 700

  4. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kühle - JAMA Neurology 2023 cited by 275

  5. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stéphan A. Botez, Michaela Týblová, Michala Jakubíková, Jana Junkerová, John Vissing, Nanna Witting, Sonja Holm‐Yildiz, Mads Stemmerik, Henning Andersen, Izabella Obál, Guilhem Solé, Stéphane Mathis, Marie‐Hélène Violleau, Christine Tranchant, Sihame Messai, Jean‐Baptiste Chanson, Aleksandra Nadaj‐Pakleza, Arnaud Verloes, Leila Zaidi, Sabrina Sacconi, Manuela Gambella, Michele Cavalli, Tanya Stojkovic, Sophie Demeret, Loïc Le Guennec, Giorgia Querin, Nicolas Weiss, Marion Masingue, Laurent Magy, Karima Ghorab, Ia Rukhadze, Alexander Tsiskaridze, Marina Janelidze, Temur Margania, Florian Then Bergh, Eike Hänsel, Andrea Kalb, Bianca Meilick, Mandy Reuschel, Lars-Malte Teußer, Astrid Unterlauft, Clemens Goedel, Tim Hagenacker, Andreas Totzeck, Benjamin Stolte, Franz Blaes, Christine Bindler, Vasilios Tsoutsikas, Annekathrin Roediger, Christian Geis, Jens Schmidt, Jana Zschüntzsch, Margret Schwarz, Stefanie Meyer, Karsten Kummer, Stefanie Glaubitz, Rachel Zeng, Heinz Wiendl, Luisa Klotz, Anna Lammerskitten, Jan D. Lünemann, Péter Diószeghy, Renato Mantegazza, Lorenzo Maggi, Elena Rinaldi, Matteo Gastaldi, Federico Mazzacane, Pietro Businaro, Raffaele Iorio, Giovanni Antonini and 193 more - The Lancet Neurology 2023 cited by 260

  6. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

    Authors: , , , , , , , , , , , , , - Nature Communications 2020 cited by 454

  7. Bruton tyrosine kinase inhibitors for multiple sclerosis

    Authors: , , , - Nature Reviews Neurology 2023 cited by 184

  8. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Multiple Sclerosis Journal 2018 cited by 705

  9. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fritz Leutmezer, Volker Limmroth, Jan D. Lünemann, Andreas Lutterotti, Sven G. Meuth, Uta Meyding‐Lamadé, Michael Platten, Peter Rieckmann, Stephan Schmidt, Hayrettin Tumani, Frank Weber, Martin S. Weber, Uwe K. Zettl, Tjalf Ziemssen, Frauke Zipp, for the ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG) - Therapeutic Advances in Neurological Disorders 2021 cited by 191

  10. Stroke induces disease-specific myeloid cells in the brain parenchyma and pia

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 120

  11. Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges

    Authors: , , , , , , , , , , , , , , , , , , - Nature Neuroscience 2021 cited by 180

  12. CD4+T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients

    Authors: , , , , , , , - Neuro-Oncology 2015 cited by 170

  13. Guideline for the management of myasthenic syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Therapeutic Advances in Neurological Disorders 2023 cited by 159

  14. A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis

    Authors: , , , , , , , , , , , , , , - Science Translational Medicine 2022 cited by 87

  15. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

    Authors: , , , , , , , , , , - Multiple Sclerosis Journal 2017 cited by 150

  16. Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2022 cited by 85

  17. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

    Authors: , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2020 cited by 164

  18. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid

    Authors: , , , , , , , , , , , , , , , , , - Immunity 2020 cited by 187

  19. Association of obesity with disease outcome in multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2022 cited by 86

  20. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisabeth Gulowsen Celius, Helle Bach Søndergaard, Jesper Tegnér, Hanne F. Harbo, Annette Oturai, Sigurgeir Ólafsson, Hannes P. Eggertsson, Bjarni V. Halldórsson, Haukur Hjaltason, Elías Ólafsson, Ingileif Jónsdóttir, Kāri Stefánsson, Tomas Olsson, Fredrik Piehl, Tomas J. Ekström, Ingrid Kockum, Andrew P. Feinberg, Maja Jagodic - Nature Communications 2018 cited by 212

  21. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frauke Zipp - EBioMedicine 2020 cited by 131

  22. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

    Authors: , , , , , , , , , , , , , , , , , , , - Multiple Sclerosis Journal 2022 cited by 78

  23. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 53

  24. Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis

    Authors: , , , , , , , , , , , - Translational Stroke Research 2021 cited by 78